Pay-for-Performance in the US: What Could Work, What Won't
In theory, pay-for-performance (P4P) contracts could be highly desirable tools to address shifting dynamics of the pharma market, but, in practice, they’re likely to remain rare because they’re expensive and complicated to implement. Two recent, high-profile collaborations between pharma companies and payors in the US highlight growing interest in P4P arrangements, but experts are divided over whether they can be widely emulated.
You may also be interested in...
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
The global pharmaceutical industry is facing decreasing margins triggered by various internal and external reasons. To address the crisis effectively long term, we see pharma’s integration into care management, combined with data generation and analysis of real-world outcomes, as a way to charge for the value pharma adds.
A wave of research-based collaborations between pharmaceutical companies and payors is enabling a new level of credibility, trust, and joint efforts to enhance patient care.